Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant atezolizumab plus chemotherapy vs chemotherapy in operable triple-negative breast cancer
jRCT2080223970Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Started Jul 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2080223970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223970.